Risk of hepatitis B reactivation in HBsAg−/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta‐analysis

BACKGROUND: The risk of hepatitis B virus (HBV) reactivation after biologic and targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) therapy in patients with rheumatoid arthritis (RA) combined with HBsAg–/HBcAb+ is still inconsistent. METHODS: We conducted a systematic review of exi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Xuezhi, Xiao, Yanhua, Xu, Liyan, Liu, Lei, Mo, Hailu, Mo, Hanyou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910170/
https://www.ncbi.nlm.nih.gov/pubmed/36840482
http://dx.doi.org/10.1002/iid3.780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910170/
https://www.ncbi.nlm.nih.gov/pubmed/36840482
http://dx.doi.org/10.1002/iid3.780

Ejemplares similares